[{"id":"444f47db-cfc2-467e-844b-6c0f5568dcc4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04096638","created_at":"2021-01-18T20:02:44.860Z","updated_at":"2024-07-02T16:35:16.277Z","phase":"Phase 1","brief_title":"Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04096638","lead_sponsor":"invoX Pharma Limited","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • SB 11285"],"overall_status":"Recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 09/23/2019","start_date":" 09/23/2019","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2024-03-06"}]